May 14, 2020
According to the research report titled ‘Global Syphilis Immunoassay Diagnostics Market Size study, by Product (Analyzer and Kits & Reagents), Technology (ELISA, CLIA & Others), by End-User (Hospitals, Diagnostic Lab, Blood Banks and Others) and Regional Forecasts 2020-2026’, available with Market Study Report LLC, global syphilis immunoassay diagnostics market was worth USD 21.42 billion in 2019 and is expected to grow with a CAGR of 6.1% between 2020 and 2026.
Syphilis is a chronic bacterial disease and can be treated with antibodies, especially in the early stage of the disease development. It spread via unprotected intercourse. Diagnosis of syphilis requires high level of clinical supervision and routine screening of population. The disease can be diagnosed by testing samples of blood to confirm the presence of antibodies that the body produces to fight the infection. These tests identify the current as well as previous cases of infection.
Rising incidences of unprotected intercourse have increased the pervasiveness of syphilis infection, which in turn is a major factor driving the growth of global syphilis immunoassay diagnostics industry. The market is expected to amplify further owing to favorable government initiatives to curb the spread of diseases. For instance, various regional governments in Europe and U.S. are conducting complete syphilis screening and treatment among expecting women. Similarly, several nonprofit organizations organized maternal syphilis workshops for creating awareness regarding child and maternal health in 25 African countries in 2017. However, lack of cognizance pertaining to syphilis and its diagnosis may hinder the market growth.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2610798/
As per product type, the market is divided into kits & reagents and analyzers, whereas in terms of technology, the industry is split into CLIA, ELISA and others. Based on end-user landscape, syphilis immunoassay diagnostics industry is categorized into blood banks, diagnostic labs, hospitals and others.
Considering the geographical landscape, syphilis immunoassay diagnostics market in North America is expected to record a momentous growth rate during the estimated timeframe, primarily due to high occurrence of syphilis infection.
Meanwhile, Asia-Pacific market is projected to grow significantly during the forecast period. Numerous initiatives by public and private entities which promote diagnosis of syphilis is favoring the market scenario in APAC.
Fujirebio (Miraca Group), BioMerieux SA, Shenzhen New Industries Biomedical Engineering Co. Ltd., Ortho Clinical Diagnostics, Abbott Laboratories, DiaSorin S.p.A., Siemens Healthineers AG, Becton Dickinson (BD), Bio-Rad Laboratories Inc. and F. Hoffman-La Roche AG are the major contenders in worldwide syphilis immunoassay diagnostics industry.